What does the NCCN recommend for salvage therapy in patients with multiple myeloma (MM)?

Updated: May 11, 2021
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

For salvage therapy, the regimen used for primary induction can be repeated if relapse occurs after more than 6 months. Otherwise, category 1 preferred regimens include the following [2] :

  • Carfilzomib/lenalidomide/dexamethasone
  • Daratumumab/bortezomib/dexamethasone
  • Daratumumab/carfilzomib/dexamethasone
  • Daratumumab/lenalidomide/dexamethasone
  • Isatuximab-irfc/pomalidomide/dexamethasone
  • Ixazomib/pomalidomide/dexamethasone
  • Pomalidomide/bortezomib/dexamethasone

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!